Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.0650 (6.97%) ($4.8500 - $5.3000) on Mon. Aug. 24, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.86% (three month average) | RSI | 87 | Latest Price | $5.0650(6.97%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 38.6% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) VCSH(47%) BNDX(37%) BND(34%) TIP(31%) EDOC(30%) | Factors Impacting ADMS price | ADMS will decline at least -3.93% in a week (0% probabilities). XLE(-18%) OIH(-17%) TBT(-16%) IFRA(-16%) XOP(-15%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.93% (StdDev 7.86%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $4.78(5.96%) | 10 Day Moving Average | $4.1(23.54%) | 20 Day Moving Average | $3.36(50.74%) | To recent high | 0% | To recent low | 0% | Market Cap | $N/A | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |